基于肿瘤免疫微环境的肝癌分子分型研究进展  

Research progress in molecular classification of liver cancer based on tumor immunological microenvironment

作　　者：刘菲(综述) 隋红(审校)[1] LIU Fei;SUI Hong(Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,哈尔滨150081

出　　处：《实用肿瘤学杂志》2021年第6期557-561,共5页Practical Oncology Journal

基　　金：哈尔滨医科大学海燕科研基金(编号:JJZD2019-08)。

摘　　要：免疫治疗改善了肝癌整体治疗策略,其特有的免疫异质特征和对免疫微环境的高度耐受使免疫治疗进入瓶颈阶段,因此对于可能受益于免疫检查点治疗的患者来说,划分肝癌分子分型是必要的。随着二代测序技术的进步,科学家根据浸润性免疫细胞丰度、免疫检查点表达水平、多组学数据、免疫抑制互斥机制及肿瘤微环境异质性等各个层面进行分子分型探索,不仅将肝癌特定生物学、分子和临床病理特征与肿瘤微环境关联,而且显示出与转录组分子分型的重叠之处,有利于未来肝癌的诊断、治疗方式选择和预测临床结局,推动精确的肝癌个体化免疫治疗。Immunotherapy improves the overall treatment strategy of liver cancer.Its unique immune heterogeneity and high tolerance to immune microenvironment make immunotherapy enter the bottleneck stage.Therefore,it is necessary to classify molecular classifications of liver cancer patients who may benefit from immune checkpoint therapy.With the progress of next-generation sequencing technology,scientists have explored molecular classifications based on the abundance of infiltrating immune cells,the expression of immune checkpoints,multi-omics data,mutually exclusive mechanisms for immunosuppression and the heterogeneity of tumor microenvironment.It is not only the specific biological,molecular and clinicopathological characteristics of liver cancer associated with the tumor microenvironment,but it also shows the overlap with the molecular classifications of the transcriptome.It is beneficial to the diagnosis of liver cancer,the choice of treatment methods and the prediction of clinical outcomes,and promotes accurate individualized immunotherapy for liver cancer.

关 键 词：肝细胞癌 肿瘤免疫微环境 分子分型 免疫检查点抑制剂 

分 类 号：R735.7[医药卫生—肿瘤]